/
/
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
È necessario avere un abbonamento a JoVE per visualizzare questo. Accedi o inizia la tua prova gratuita.
Capitoli
- 00:04Introduction
- 00:53Plate Coating
- 01:58Seeding of Human iPSC‐Derived Cardiomyocytes into Flexible 96‐Well Plates (Day 0)
- 02:56Medium Exchange of Flexible 96‐Well Plates (Day 1)
- 03:53Final Medium Exchange Before Compound Addition (Day 5–7)
- 04:21Compound Addition and Data Recording (Day 5–7)
- 05:47Results: Contractility Assessment, Base Impedance, and EFP Recordings of Human iPSC‐Derived Cardiomyocytes After Drug Treatment
- 07:35Conclusion
The analysis of changes in contractile function and cellular integrity of human iPSC-derived cardiomyocytes is of immense importance for nonclinical drug development. A hybrid 96-well cell analysis system addresses both parameters in a real-time and physiological manner for reliable, human-relevant results, necessary for a safe transition into clinical stages.
